Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.70 |
| ▸ | PARP1 | P09874 | 1/20 | 0.69 |
| ▸ | F2R | P25116 | 1/20 | 0.69 |
| ▸ | MGLL | Q99685 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025738 | 0.95 | NR1H4 (0.72) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL20227586 | 0.95 | KCNK3 (0.79) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL13601057 | 0.93 | HDAC8 (0.71) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL678664 | 0.92 | MEN1 (0.75) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL6451496 | 0.90 | KMT2A (0.73) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL8745242 | 0.90 | PTPN1 (0.77) | KMT2APOLBKCNK3KCNK9PARP1 | |
| SCHEMBL27760395 | 0.89 | PTPN1 (0.76) | MEN1KMT2APARP1F2RNR1H4 | |
| SCHEMBL25694006 | 0.89 | KCNK3 (0.80) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL27984049 | 0.87 | MEN1 (0.74) | MEN1KMT2APOLBKCNK3KCNK9 | |
| SCHEMBL5943892 | 0.87 | MEN1 (0.71) | MEN1KMT2APARP1F2RNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | MEN1 3477/4885KMT2A 1947/4885POLB 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.